26 November
2024
Quadrise Plc
("Quadrise" or the "Company")
Collaboration and Operational Trial Agreement
with MSC and Cargill
Quadrise
Plc (AIM: QED), the supplier of innovative energy solutions for a
cleaner planet, is delighted to announce the signature of a
Collaboration and Operational Trial Agreement (the "Project
Agreement") with MSC Shipmanagement Ltd ("MSC") and Cargill NV
("Cargill"), paving the way for the long-awaited vessel trials on
board the MSC Leandra (the "Trials").
Further to
the Company's announcement of 10 July 2024, and under the
Project
Agreement,
Quadrise, MSC and Cargill have agreed their respective obligations under which
the Company's fuels, bioMSAR™ and MSAR®, will be produced at the
MAC2 facility in Antwerp, Belgium using feedstocks
supplied by Cargill and then sold by Cargill to MSC for the
Trials.
The parties
to the Project
Agreement will use
their reasonable endeavours to contribute towards the successful
Trials and to receipt of a final Letter of No Objection from
Wärtsilä following 4,000
hours of bioMSAR™ testing, with:
· Quadrise providing equipment, additives
and technical expertise; and
· MSC providing the trial vessel, MSC Leandra,
necessary flag state approvals for the Trials and procuring
professional monitoring services for the Trials; and
· Cargill providing the necessary
feedstocks, transportation of fuels and operational and logistical
support.
MAC2 have already
received the required
operating permits for installation of Quadrise equipment and have
prepared the site. Following signature of the
Project
Agreement, final
work to enable Quadrise equipment to be delivered to the
MAC2 site can now be completed, enabling the Trials to
commence before end Q1 2025.
In
parallel, bilateral agreements, including a toll manufacturing
agreement between Cargill and Quadrise in respect of fuel
manufacture, can be finalised now that the outline commercial terms
have been agreed in the Project Agreement.
Upon
successful conclusion of the Trials, MSC, Cargill and Quadrise will
negotiate and enter into a definitive long-term Commercial
Agreement.
The Project Agreement will expire on the sooner of: (1) One year
following completion of the Trials; (2) Commencement of a
Commercial Agreement.
Commenting
on this agreement Jason Miles, CEO of Quadrise, said:
"Quadrise is delighted to have signed this pivotal
agreement with MSC and Cargill, which triggers the process for the
trials to get underway. We are hugely excited to be partnering with
world-leading Companies to demonstrate the commercial viability and
environmental benefits of our technology and the contribution it
can make to decarbonisation of the shipping sector. Having already
successfully demonstrated MSAR® on
the trial vessel, we are highly confident of a successful trial
result on bioMSAR™ and the substantial commercial opportunities
that this will lead to."
About the MSC Vessel Trials
The Trials
will be carried out on the MSC Leandra, previously used for prior
successful MSAR® demonstrations, following the installation and
commissioning of Quadrise equipment at the MAC2 facility
in Antwerp, Belgium and
are expected to
commence before end Q1 2025.
The Trials
will commence with Proof of Concept ('POC') tests using MSAR® and
bioMSAR™. Each POC
Trial is estimated to require around 1,000 metric tons ("MT") of
fuel to confirm engine performance on the vessel.
Subject to
positive results from the POC Trials, the fuels will undergo
subsequent trials to provide commercial operating experience with a
view to obtaining Letters of No Objection ("LONOs") from the engine
manufacturer after confirming the operational viability
of bioMSAR™ and
MSAR® at both an interim (midway) and final stage
(after circa 4,000 operating hours). During the LONOs it is planned that barge
deliveries of up to 1,500MT of Quadrise fuels will be supplied to
the MSC vessel every 4-6 weeks for the Trials, over a period of 6-8
months.
Upon
completion of the Trials and receipt of the LONO, or when
sufficient progress has been demonstrated to the satisfaction of
MSC, Cargill and Quadrise (the "Parties"), the Parties plan to
conclude long-term commercial agreements within three months of
achieving this milestone.
Additionally, MSC and Quadrise will continue
discussions with other marine engine suppliers to investigate
testing bioMSAR™ and MSAR® on their engines and will also explore opportunities to
test the Quadrise Blend-on-Board solution which will open up new
possibilities for tramping vessels and provide additional
flexibility on bioMSAR™ supply.
For
additional information, please contact:
Quadrise Plc
|
|
+44 (0)20 7031 7321
|
Andy
Morrison, Chairman
Jason
Miles, Chief Executive Officer
|
|
|
|
|
|
Nominated Adviser
|
|
|
Cavendish Capital Markets
Limited
|
|
+44 (0)20 7220 0500
|
Ben
Jeynes
Katy
Birkin
George
Lawson
|
|
|
|
|
|
Joint Brokers
|
|
|
Shore Capital Stockbrokers
Limited
Toby Gibbs,
Rachel Goldstein (Corporate Advisory)
Fiona
Conroy (Corporate Broking)
|
|
+44 (0)20 7408 4090
|
VSA Capital Limited
Andrew Raca
(Corporate Finance)
Andrew Monk
(Corporate Broking)
|
|
+44 (0)20 3005 5000
|
|
|
|
Public & Investor
Relations
|
|
|
Cutbill Jacoby
Andy
Cutbill
Frankie
Dundon
|
|
+44 (0)7841 576000
+44 (0)7312 274086
|
About Quadrise:
Quadrise is
the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and
biofuels, providing innovative solutions to lower energy costs,
pollution and greenhouse gas emissions today for the global power
generation, shipping, industrial and oil industries.
Learn more
at:
www.quadrise.com
Follow us on social
media:
LinkedIn:
@Quadrise Plc
X (formerly
Twitter):
@QuadrisePlc
This announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.